DiosCURE Therapeutics SE announced today that it has signed an exclusive licensing agreement with the research and invention parties University of Bonn, University Hospital Bonn, Scripps Research and Macrostruct Holding & Consulting AB, for a broad suite of intellectual property, including the single-domain antibodies, DIOS-202, DIOS-203 and DIOS-301, currently in preclinical development as a potential differentiated, highly-efficacious therapy against SARS-CoV-2. Under the terms of the agreement, DiosCURE is the exclusive, worldwide licensor for the lead drug candidates DIOS-202, DIOS-203 and DIOS-301 and has prioritized access to all future candidates resulting from the research collaboration. DIOS-202, DIOS-203 and DIOS-301 are multivalent single-chain antibodies with unique molecular modes-of-action to inactivate SARS-CoV-2 virions.